238 related articles for article (PubMed ID: 22782520)
1. Cost-effectiveness of disease-modifying therapies in multiple sclerosis.
Manouchehrinia A; Constantinescu CS
Curr Neurol Neurosci Rep; 2012 Oct; 12(5):592-600. PubMed ID: 22782520
[TBL] [Abstract][Full Text] [Related]
2. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.
Tappenden P; McCabe C; Chilcott J; Simpson E; Nixon R; Madan J; Fisk JD; Brown M
Value Health; 2009; 12(5):657-65. PubMed ID: 19508662
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
[TBL] [Abstract][Full Text] [Related]
5. Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA.
Hartung DM
Neurotherapeutics; 2017 Oct; 14(4):1018-1026. PubMed ID: 28812229
[TBL] [Abstract][Full Text] [Related]
6. The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden.
Kotsopoulos N; Connolly MP; Dort T; Kavaliunas A
J Med Econ; 2020 Aug; 23(8):831-837. PubMed ID: 32400258
[No Abstract] [Full Text] [Related]
7. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
Hawton A; Shearer J; Goodwin E; Green C
Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
[TBL] [Abstract][Full Text] [Related]
8. Incorporating patients' preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review.
Ngorsuraches S; Poudel N
Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):183-195. PubMed ID: 33472451
[No Abstract] [Full Text] [Related]
9. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.
Phillips CJ
CNS Drugs; 2004; 18(9):561-74. PubMed ID: 15222773
[TBL] [Abstract][Full Text] [Related]
10. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America.
Burt RK; Tappenden P; Han X; Quigley K; Arnautovic I; Sharrack B; Snowden JA; Hartung D
Mult Scler Relat Disord; 2020 Oct; 45():102404. PubMed ID: 32731201
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomics of synthetic therapies for multiple sclerosis.
D'Amico E; Chisari CG; Gitto L; Zanghì A; Toscano S; Patti F
Expert Opin Pharmacother; 2019 Aug; 20(11):1331-1340. PubMed ID: 31090469
[No Abstract] [Full Text] [Related]
12. Health economic issues in MS.
Kobelt G
Int MS J; 2006 Jan; 13(1):17-26, 16. PubMed ID: 16420781
[TBL] [Abstract][Full Text] [Related]
13. Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.
Hartung DM
Curr Neurol Neurosci Rep; 2021 May; 21(7):28. PubMed ID: 33948740
[TBL] [Abstract][Full Text] [Related]
14. Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?
Batcheller L; Baker D
J Neurol Sci; 2019 Sep; 404():19-28. PubMed ID: 31323518
[TBL] [Abstract][Full Text] [Related]
15. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
16. There is much to be learnt about the costs of multiple sclerosis in Latin America.
Romano M; Machnicki G; Rojas JI; Frider N; Correale J
Arq Neuropsiquiatr; 2013 Aug; 71(8):549-55. PubMed ID: 23982015
[TBL] [Abstract][Full Text] [Related]
17. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
Rotstein Z; Hazan R; Barak Y; Achiron A
Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
[TBL] [Abstract][Full Text] [Related]
18. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.
Karampampa K; Gustavsson A; Miltenburger C; Kindundu CM; Selchen DH
J Popul Ther Clin Pharmacol; 2012; 19(1):e11-25. PubMed ID: 22247419
[TBL] [Abstract][Full Text] [Related]
19. Managed care aspects of managing multiple sclerosis.
Owens GM
Am J Manag Care; 2013 Nov; 19(16 Suppl):s307-12. PubMed ID: 24494620
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.
Amato MP
Expert Opin Pharmacother; 2004 Oct; 5(10):2115-26. PubMed ID: 15461547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
